Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). Methods: Gene expression was measured in patients with febrile SJIA and in matched healthy controls by Affymetrix DNA microarrays. Transcriptional response was assessed by gene expression changes from baseline to day 3 using adapted JIA American College of Rheumatology (aACR) response criteria (50 aACR JIA). Changes in pro-inflammatory cytokines IL-6 and IL-18 were assessed up to day 197. Results: Microarray analysis identified 984 probe sets differentially expressed (≥2-fold difference; P < 0.05) in patients versus controls. Over 50% of patients with ≥50 aACR JIA were recognizable by baseline expression values. Analysis of gene expression profiles from patients achieving ≥50 aACR JIA response at day 15 identified 102 probe sets differentially expressed upon treatment (≥2-fold difference; P < 0.05) on day 3 versus baseline, including IL-1β, IL-1 receptors (IL1-R1 and IL1-R2), IL-1 receptor accessory protein (IL1-RAP), and IL-6. The strongest clinical response was observed in patients with higher baseline expression of dysregulated genes and a strong transcriptional response on day 3. IL-6 declined by day 3 (≥8-fold decline; P < 0.0001) and remained suppressed. IL-18 declined on day 57 (≥1.5-fold decline, P ≤ 0.002). Conclusions: Treatment with canakinumab in SJIA patients resulted in downregulation of innate immune response genes and reductions in IL-6 and clinical symptoms. Additional research is needed to investigate potential differences in the disease mechanisms in patients with heterogeneous gene transcription profiles.

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy / A.H. Brachat, A.A. Grom, N. Wulffraat, H.I. Brunner, P. Quartier, R. Brik, L. McCann, H. Ozdogan, L. Rutkowska-Sak, R. Schneider, V. Gerloni, L. Harel, M. Terreri, K. Houghton, R. Joos, D. Kingsbury, J.M. Lopez-Benitez, S. Bek, M. Schumacher, M.-. Valentin, H. Gram, K. Abrams, A. Martini, D.J. Lovell, N.R. Nirmala, N. Ruperto, R. Cuttica, W. Emminger, B. Lauwerys, C. Wouters, L. Goffin, F. Sztajnbok, S. Radominski, S. Oliveira, E. Haddad, I. Kone-Paut, M. Desjonqueres, M. Fischbach, A. Thon, D. Foell, E. Weibarth-Riedel, G. Horneff, R. Trauzeddel, R. Berner, T. Kallinich, M. Trachana, T. Constantin, J. Barash, Y. Berkun, Y. Uziel, F. Corona, M. Alessio, R. Cimaz, S. Viola, B. Flato, M. Ferrandiz, I. Calvo, J. Anton, J.C. Robledillos, M.L. Gamir, B. Magnusson, M. Hofer, E. Unsal, M. Erguven, S. Ozen, N. Wilkinson, A. Chieng, A. Ramanan, H. Foster, K. Nistala, G. Higgins, K. Marzan, K. Schikler, P. Morris. - In: ARTHRITIS RESEARCH & THERAPY. - ISSN 1478-6354. - 19(2017), pp. 13.1-13.10. [10.1186/s13075-016-1212-x]

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

R. Cimaz;
2017

Abstract

Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). Methods: Gene expression was measured in patients with febrile SJIA and in matched healthy controls by Affymetrix DNA microarrays. Transcriptional response was assessed by gene expression changes from baseline to day 3 using adapted JIA American College of Rheumatology (aACR) response criteria (50 aACR JIA). Changes in pro-inflammatory cytokines IL-6 and IL-18 were assessed up to day 197. Results: Microarray analysis identified 984 probe sets differentially expressed (≥2-fold difference; P < 0.05) in patients versus controls. Over 50% of patients with ≥50 aACR JIA were recognizable by baseline expression values. Analysis of gene expression profiles from patients achieving ≥50 aACR JIA response at day 15 identified 102 probe sets differentially expressed upon treatment (≥2-fold difference; P < 0.05) on day 3 versus baseline, including IL-1β, IL-1 receptors (IL1-R1 and IL1-R2), IL-1 receptor accessory protein (IL1-RAP), and IL-6. The strongest clinical response was observed in patients with higher baseline expression of dysregulated genes and a strong transcriptional response on day 3. IL-6 declined by day 3 (≥8-fold decline; P < 0.0001) and remained suppressed. IL-18 declined on day 57 (≥1.5-fold decline, P ≤ 0.002). Conclusions: Treatment with canakinumab in SJIA patients resulted in downregulation of innate immune response genes and reductions in IL-6 and clinical symptoms. Additional research is needed to investigate potential differences in the disease mechanisms in patients with heterogeneous gene transcription profiles.
Biomarkers; Canakinumab; Gene expression; Interleukin-1β; Juvenile idiopathic arthritis; SJIA
Settore MED/16 - Reumatologia
2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
early changes.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 4.89 MB
Formato Adobe PDF
4.89 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/766090
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 43
social impact